Nuveen’s Codiak BioSciences, Inc. Common Stock CDAK Stock Holding History

Nuveen’s Portfolio CDAK Stock Details CDAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-37,184	Closed	-$234K	–	3582
2022 Q1	$234K	Hold	37,184	–	–	﹤0.01%	3162
2021 Q4	$445K	Hold	37,184	–	–	﹤0.01%	3098
2021 Q3	$711K	Hold	37,184	–	–	﹤0.01%	3097
2021 Q2	$689K	Buy	+37,184	New	+$714K	﹤0.01%	3117
2021 Q1	–	Sell	-9,141	Closed	-$295K	–	3412
2020 Q4	$295K	Buy	+9,141	New	+$121K	﹤0.01%	3139

Other funds holding CDAK

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

UOTTAIMCU

University of Texas/Texas AM Investment Management Co (UTIMCO) Austin, Texas $687M AUM 21.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return

OIM

Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Nuveen's CDAK Position: Q2 2022 in Review

Nuveen sold out of Codiak BioSciences, Inc. Common Stock (CDAK) in Q2 2022, closing a stake of 37,184 shares — an estimated $234K sold.

Nuveen first reported a position in CDAK in Q4 2020 and held it in 5 quarters. The position peaked at $711K in Q3 2021. 49 funds tracked by Wall St. Rank hold CDAK as of Q2 2022.

Nuveen reported no remaining Codiak BioSciences, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
Nuveen sold 37,184 Codiak BioSciences, Inc. Common Stock shares in Q2 2022, an estimated $234K.
Nuveen first reported a position in Codiak BioSciences, Inc. Common Stock in Q4 2020 and held it in 5 quarters.
Nuveen's Codiak BioSciences, Inc. Common Stock position peaked at $711K in Q3 2021.
49 funds tracked by Wall St. Rank held Codiak BioSciences, Inc. Common Stock as of Q2 2022.

Based on Nuveen's 13F filing for Q2 2022, filed 15 Aug 2022.